Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition

Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition

Roivant Sciences has agreed to merge with Montes Archimedes Acquisition (MAAC), a Nasdaq-listed special purpose acquisition company, in a deal that values the Swiss biopharma company at $7.3 billion. Montes Archimedes Acquisition is sponsored by health care investment firm Patient Square Capital. The deal is expected to enable Roivant Sciences to get a listing on […]